The world’s largest ‘biological datacenter’ could help make animal testing obsolete
| Source: Fast Company AI
Tags: Vivodyne, drug discovery, organoids, AI in healthcare, animal testing, biotech, pharma
Vivodyne is building what it calls the world's largest biological datacenter — running AI-orchestrated drug experiments on lab-grown human tissue at scale — aiming to replace animal testing with human-tissue models that produce more predictive drug candidates.
Details
Biotech startup Vivodyne is developing an AI-driven platform for pharmaceutical experiments on lab-grown human tissue rather than animals. The company frames this as a 'biological datacenter': a factory-scale facility where AI orchestrates high-throughput experiments on organoids or similar human tissue models.\n\nThe potential impact spans multiple dimensions: replacing animal testing would improve pharma economics, accelerate timelines, reduce ethical controversy, and potentially yield more human-relevant results since mouse and dog biology differ significantly from human responses. AI's role appears to be in experimental design, data interpretation, and scaling tissue-based test throughput to match what animal studies currently deliver.\n\nSource content from Fast Company is limited to a one-sentence summary — detailed methodology, funding stage, or peer-reviewed results are not available from this material. This should be treated as a company announcement requiring further validation rather than independently verified research.